On Nov 02, major Wall Street analysts update their ratings for $Bristol-Myers Squibb (BMY.US)$, with price targets ranging from $36 to $60.
Morgan Stanley analyst Terence Flynn maintains with a sell rating, and adjusts the target price from $37 to $36.
BofA Securities analyst Charlie CY Yang maintains with a hold rating, and maintains the target price at $60.
Barclays analyst Carter Gould maintains with a sell rating, and maintains the target price at $43.
TD Cowen analyst Steve Scala maintains with a hold rating, and maintains the target price at $59.
Truist Financial analyst Srikripa Devarakonda maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Bristol-Myers Squibb (BMY.US)$'s main analysts recently are as follows:
Bristol Myers delivered 'decent' Q3 results, surpassing expectations on revenues and earnings per share, primarily due to the performance of the now off-patent Revlimid. With the growth portfolio showing signs of improvement, there is a cautiously optimistic view on the stock's prospects. Forecasts for 2024 revenue and earnings per share have been adjusted upwards, reflecting this sentiment. Notwithstanding this positive outlook, a degree of neutrality is maintained due to ongoing uncertainties surrounding the longer-term earnings potential.
Here are the latest investment ratings and price targets for $Bristol-Myers Squibb (BMY.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
